Skip to main content

Grafa News and Videos — Page 1155

Grafa Headlines

Latest

Grafa

Agios discontinues tebapivat program in lower-risk myelodysplastic syndromes after Phase 2b trial fails

Agios Pharmaceuticals (NASDAQ:AGIO) announced that it will discontinue the clinical development of its investigational oral therapy tebapivat for lower-risk myelodysplastic syndromes (LR-MDS) after a Phase 2b study failed to meet its predefined threshold for advancement.

Read more: Agios discontinues tebapivat program in lower-risk myelodysplastic syndromes after Phase 2b trial fails
Grafa

CollPlant explores strategic options as revenue drops following milestone loss

CollPlant Biotechnologies (NASDAQ:CLGN) initiated a formal review of its strategic alternatives after a sharp contraction in milestone revenue caused its first-quarter sales to drop to near-zero, forcing the company to slash its workforce by half.

Read more: CollPlant explores strategic options as revenue drops following milestone loss
Grafa

Merck secures FDA breakthrough status for Calderasib and Keytruda lung cancer combination

Merck (NYSE:MRK) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to its investigational oral drug calderasib when paired with the company’s blockbuster immunotherapy Keytruda, accelerating its development path for newly diagnosed lung cancer patients.

Read more: Merck secures FDA breakthrough status for Calderasib and Keytruda lung cancer combination
Grafa

BeOne Medicines showcases sustained leukemia control with long-term Brukinsa data

BeOne Medicines (NASDAQ:ONC) is moving to advance the treatment paradigm for chronic lymphocytic leukemia (CLL) with extensive long-term follow-up data slated for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Read more: BeOne Medicines showcases sustained leukemia control with long-term Brukinsa data

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift